Jeffrey J. Kraws,
Chief Executive Officer and Co-Founder
Jeffrey J. Kraws is chief executive officer and co-founder of Crystal Research Associates. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry (see Awards section). Prior to founding the Company, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co., and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo.
Karen B. Goldfarb
President, Chief Operating Officer, and Co-Founder
Karen B. Goldfarb is president, chief operating officer, and co-founder of Crystal Research Associates, bringing over sixteen years of Wall Street experience and a formidable background in the research industry. Ms. Goldfarb served as associate director of competitive analysis for IRG, and as vice president within the healthcare research group at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company), covering large-capitalization pharmaceutical, specialty pharmaceutical, generic, drug delivery, biopharmaceutical, and medical technology companies. Prior to joining Gruntal, Ms. Goldfarb served as pharmaceutical associate at First Union Securities (formerly EVEREN Securities), and as a researcher for Merrill Lynch in New York City, specializing in the paper and forest products sector. Ms. Goldfarb holds a B.A. degree in Economics from Rutgers College, New Brunswick, NJ.